Show simple item record

dc.contributor.authorDevrim-Uecok, Muege
dc.contributor.authorUcok, Alp
dc.contributor.authorKeskin-Ergen, H. Yasemin
dc.date.accessioned2021-03-06T10:10:05Z
dc.date.available2021-03-06T10:10:05Z
dc.date.issued2008
dc.identifier.citationDevrim-Uecok M., Keskin-Ergen H. Y. , Ucok A., "P50 gating at acute and post-acute phases of first-episode schizophrenia", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, cilt.32, ss.1952-1956, 2008
dc.identifier.issn0278-5846
dc.identifier.otherav_e90e87c3-1192-44de-b492-01e141ab225a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/153155
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2008.09.018
dc.description.abstractDeficit in P50 sensory gating has repeatedly been shown in schizophrenia. In order to determine the contribution of trait and/or state features to P50 gating deficit in schizophrenia we evaluated the P50 gating in patients with first-episode schizophrenia (FES) at acute and post-acute phases. Subject groups comprised 16 patients with FES and 24 healthy controls. Patients were tested at the acute phase of the illness and retested at the post-acute phase when their positive symptoms improved. During the testing at the acute phase five patients were neuroleptic-naive and the others were taking atypical antipsychotics which were started recently in order to control the acute excitation. Patients were receiving risperidone, olanzapine or quetiapine treatment at the post-acute phase. P50 gating was impaired in patients at the acute phase compared to controls. However, at the post-acute phase P50 gating was increased compared to the acute phase, reaching to the gating values of controls. P50 gating improvement might be emerged from atypical antipsychotic medication, although this can only be definitively determined by randomized studies including different antipsychotics. (C) 2008 Elsevier Inc. All rights reserved.
dc.language.isoeng
dc.subjectPsikiyatri
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSinirbilim ve Davranış
dc.subjectNEUROSCIENCES
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectKLİNİK NEUROLOJİ
dc.titleP50 gating at acute and post-acute phases of first-episode schizophrenia
dc.typeMakale
dc.relation.journalPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume32
dc.identifier.issue8
dc.identifier.startpage1952
dc.identifier.endpage1956
dc.contributor.firstauthorID190153


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record